FAQ

SN30000

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2017
024620102017

Related topics

Related topics

1 relation

Broader (1)

CEN-209

Related mentions per year

Related mentions per year

2010-2017
201020122014201620182020
SN30000
CEN-209

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs.
Hypoxia is a prevalent feature of many tumors contributing to disease progression and treatment resistance, and therefore… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 4
  • table 2
Is this relevant?
2014
2014
Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5.
SN30000 is a second-generation benzotriazine-N-oxide hypoxia-activated prodrug scheduled for clinical trial. Previously we showed… (More)
Is this relevant?
2014
2014
Characterisation of radicals formed by the triazine 1,4-dioxide hypoxia-activated prodrug, SN30000.
The radical species underlying the activity of the bioreductive anticancer prodrug, SN30000, have been identified by electron… (More)
Is this relevant?
2014
2014
Photodegradation of the benzotriazine 1,4-Di-N-oxide hypoxia-activated prodrug SN30000 in aqueous solution.
SN30000 is a benzotriazine di-N-oxide which is selectively toxic to radio-resistant hypoxic cells in tumours. Given the complex… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs.
The nitro-chloromethylbenzindoline prodrug SN29428 has been rationally designed to target tumour hypoxia. SN29428 is metabolised… (More)
Is this relevant?
2013
2013
18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model.
UNLABELLED Hypoxia is a significant therapeutic problem for solid tumors because hypoxic cells are treatment-resistant and more… (More)
Is this relevant?
2012
2012
Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.
CEN-209 (SN30000) is a second-generation benzotriazine di-N-oxide currently in advanced preclinical development as a hypoxia… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.
PURPOSE Benzotriazine-N-oxide bioreductive prodrugs such as tirapazamine and its improved analogue CEN-209 (SN30000) have… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2011
2011
EF5 as a predictive biomarker for activation of the new hypoxia-targeting prodrug SN30000.
e13597 Background: SN30000 (CEN-209), a benzotriazine-N-oxide, is a second generation analogue of tirapazamine (TPZ) and is… (More)
Is this relevant?
2010
2010
Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.
PURPOSE Tirapazamine (TPZ) has attractive features for targeting hypoxic cells in tumors but has limited clinical activity, in… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?